Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sarilumab in Patients With Giant Cell Arteritis

Next Previous
X
Search
Trial Profile

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Sarilumab in Patients With Giant Cell Arteritis

Status: Discontinued
Phase of Trial: Phase III

Latest Information Update: 10 Nov 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Sarilumab (Primary) ; Prednisone
  • Indications Giant cell arteritis
  • Focus Registrational; Therapeutic Use
  • Sponsors Sanofi

    • Most Recent Events

    • 16 Oct 2023 Results (n=83) assessing efficacy and safety of sarilumab (another IL-6Ri) in GCA published in the Arthritis Research and Therapy
    • 06 Apr 2022 This trial has been completed in Portugal trial end date is (2020-11-24) according to European Clinical Trials Database record
    • 28 Jul 2021 This trial has been completed in Slovenia (Global end date: 24 Nov 2020).

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top